CORPORATE OVERVIEW

INNOVATING TO TRANSFORM THE LIVES OF PATIENTS

September 2020

Jazz Pharmaceuticals®

Life-Changing Medicines.
Redefining Possibilities.

Forward-Looking Statements
“Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995

This slide deck and the accompanying oral presentation contain forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals’ future financial and operating results, including 2020 financial guidance, milestones and goals; the company’s growth strategy and expectations for growth, including value drivers and catalysts; future product sales, revenue and volume; planned, ongoing and future clinical trials and other product development activities and regulatory events; ongoing and future product launches; the company’s expectations regarding future competition for its products; the company’s corporate development efforts and investment activities; the timing of the foregoing events and activities; and other statements that are not historical facts. These forward-looking statements are based on the company’s current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the ultimate duration and severity of the COVID-19 pandemic and resulting global economic, financial and healthcare system disruptions and the current and potential future negative impacts to the company’s business operations and financial results; maintaining or increasing sales of and revenue from its oxybate products; effectively launching and commercializing the company’s other products and product candidates; the time-consuming and uncertain regulatory approval process, including the risk that the company’s planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in initiating or completing clinical trials; protecting and enhancing the company’s intellectual property rights; delays or problems in the supply or manufacture of the company’s products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements; government investigations, legal proceedings and other actions; obtaining and maintaining adequate coverage and reimbursement for the company’s products; identifying and acquiring, in-licensing or developing additional products or product candidates, financing these transactions and successfully integrating product candidates, products and businesses; the company’s ability to realize the anticipated benefits of its collaborations with third parties for the development of product candidates; the ability to achieve expected future financial performance and results and the uncertainty of future tax and other provisions and estimates; and other risks and uncertainties affecting the company, including those described from time to time under the caption “Risk Factors” and elsewhere in Jazz Pharmaceuticals plc’s Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and future filings and reports by the company. In addition, while the company expects the COVID-19 pandemic to continue to adversely affect its business operations and financial results, the extent of the impact on the company’s ability to generate sales of and revenues from its approved products, execute on new product launches, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration and severity of the pandemic, governmental “stay-at-home” orders and travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Ireland and other countries, and the effectiveness of actions taken globally to contain and treat the disease. Moreover, other risks and uncertainties of which the company is not currently aware may also affect the company’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this slide deck and the accompanying oral presentation are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the company on its website or otherwise. The company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Well-Positioned for Transformative Growth

STRONG COMMERCIAL FRANCHISES

#1 **Treatment for Narcolepsy**
Xyrem and planned launch of next generation Xywav

2 **New Oncology Treatments Since 2015**
Rapidly growing presence in the treatment of hematological and solid tumor cancers

35% **Adjusted Net Income CAGR**
From 2010-2019

ROBUST AND PRODUCTIVE PIPELINE

5 **Potential Product Launches**
Across 2020 - 2021

>25 **Projects in R&D Portfolio**
Expanded more than 4x since 2015

9 **Product Approvals**
Since 2015

8 **Commercial Launches**
Since 2015

INVESTING TO LEVERAGE GLOBAL PLATFORM

9 **Licensing/M&A Deals Since 2015**
Including recently approved Zepzelca

>90 **Markets Supplied Globally**
Operate in or partner to make medicines available

>$3B Available liquidity at end of 2Q20[1]

>$880M Operating cash flow LTM[2]

[1] Includes $1.7 billion in cash and investments and $1.6 billion undrawn revolving credit facility as of 6/30/20. [2] LTM= last 12 months = 7/1/19 to 6/30/20

Patient-Centric Innovation Drives our Strategy

Targeting two therapeutic areas with significant market opportunities



Commercial Portfolio of High Value Products

Continuing to deliver strong revenue growth and diversification

AIMING FOR FURTHER TOP-LINE GROWTH…



…AND ENHANCED DIVERSIFICATION BY 2022



Expect new product sales to drive nearly 50% of revenue by 2022

Includes new and planned product launches of Sunosi, Zepzelca, Xywav (narcolepsy), and the addition of JZP-458 and Xywav (IH), if approved, in 2022

xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution

ZEPZELCA (lurbinectedin)

SUNOSI (solriamfetol) tablets

JZP-458

Includes Xyrem, Defitelio, Erwinaze and Vyxeos in 2020 and Xyrem, Defitelio and Vyxeos 2022

XYREM (sodium oxybate) oral solution

DEFITELIO (defibrotide sodium)

Vyxeos (daunorubicin and cytarabine) liposome for injection

[1] Net product sales guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

Expect to Deliver Significant Value Through 2025 and Beyond

Through disciplined allocation of capital in alignment with our strategic priorities

CAPITAL

$1.7B
Cash[1]

$Billions
Expected cash flow through 2025

Significant
Leverage capacity

DISCIPLINED DEPLOYMENT

PIPELINE EXPANSION
Advancing internal assets
Licensing new assets

EXISTING PRODUCTS
New indications
Geographic expansions

CORPORATE DEVELOPMENT
Product acquisitions
Company acquisitions

SHARE REPURCHASES
Opportunistic Share Repurchases

STRATEGIC PRIORITIES

- Diversified and Growing Base of Revenues
- Differentiated Pipeline to Support Future Growth
- Operational Excellence to Maximize TSR

[1] Represents cash and investments as of June 30, 2020.

Significant Progress to Date in 2020

Providing a strong foundation for our continued transformation

Delivered strong 2Q20 financial and operational results, despite global pandemic

- Execution across the organization, enabling acceleration of pipeline
- Revenues and EPS above consensus
- >$450M in cash from operations 1H20

On track for up to 5 major product launches across 2020 – 2021

SUNOSI (solriamfetol) (IV)	ZEPZELCA (lurbinectedin) for injection 4 mg	xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution (IR)
EMA approved 1Q20 & European rolling launch initiated May 2020	FDA approved two months early (June 2020); launched in early July 2020	FDA approved July 2020 for cataplexy and EDS in narcolepsy with launch planned for 4Q20
JZP-458		**Xywav for Idiopathic Hypersomnia**
Targeting regulatory filing as early as year-end and targeting launch mid-2021		Phase 3 top-line results expected 4Q20; targeting launch 4Q21

Catalyst-rich time with multiple opportunities for future value creation

NEUROSCIENCE PORTFOLIO

Significant Momentum

Neuroscience Portfolio

Strong Commercial Execution

#1
Sleep disorder medicine by sales since 2014 (Xyrem)

>50%
of oxybate patients on Xywav by 2023

$1.7-1.8B
2020 Neuroscience net sales guidance[1]

3
On-market products anticipated by YE2020

Poised For Sustainable Growth

- Sleep franchise - enhanced durability with new differentiated standard in oxybate therapy, Xywav
- Sleep disorders - important growth opportunity given the high unmet medical needs
- Strong growth prospects for Sunosi in the U.S. and European markets (focus on narcolepsy, OSA and potential new indications)
- Expansion into new areas of unmet need including treatment of essential tremor
- Investing in pipeline with early in-licensed innovative assets with new MOAs

[1] Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

XYREM

Building the #1 Sleep Disorder Franchise

Xyrem Success Factors

- High unmet need and limited treatment options
- Developed support services for patients; navigated payer barriers
- Communicated value; addressed HCP safety concerns
- Implemented marketing efforts to support improved diagnosis and treatment
- Proven expertise in navigating complex regulatory environment and distribution system
- Established oxybate as standard of care for treatment of EDS and cataplexy in narcolepsy

NET SALES SINCE 2008

$ in millions



[1] Total neuroscience net sales guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

XYWAV: The New Differentiated Standard in Oxybate Therapy

Expect a majority of oxybate patients on Xywav by 2023

xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution ℞

LOWER-SODIUM OXYBATE FOR THE TREATMENT OF NARCOLEPSY

- 92% less sodium than Xyrem with the same active moiety for the treatment of cataplexy and EDS in patients >7 years of age with narcolepsy
- Narcolepsy is a chronic disease associated with numerous cardiovascular/cardiometabolic comorbidities[1]

A DIFFERENTIATED LABEL

- Twice-nightly option for patients with ability to take unequal first and second doses
- No warning to monitor patients sensitive to sodium intake
- HCP information on initiating new and transitioning patients from other narcolepsy therapies

EXPECT STRONG ADOPTION OF XYWAV

- Priced at parity to Xyrem with expected U.S. launch 4Q20
- Existing Xyrem patients transition to Xywav at same dose[2]
- Opportunity to add patients previously not prescribed Xyrem based on sodium concerns
- Focused on providing strong patient assistance programs and payer access

POTENTIAL FURTHER INDICATION FOR IH

- Expect top-line data from Phase 3 pivotal study of Xywav in IH 4Q20
- Targeting U.S. launch of Xywav for IH late 2021
- Significant unmet need with diagnosed prevalence of ~37,000 patients

[1] Black, J, et al. SleepMed. 2017; 33: 13-18. [2] Xywav is a CNS depressant and has a boxed warning. See appendix for details. For full prescribing information, visit www.xywav.com

Growing Neuroscience Pipeline/Portfolio

	KEY HIGHLIGHTS	GROWTH OPPORTUNITIES
SUNOSI (solriamfetol) IV U.S. Launch July 2019: European Launch May 2020	• Sunosi: first and only FDA approved dual acting DNRI to treat EDS in adults with narcolepsy or OSA • Improves wakefulness and reduces EDS • Established strong U.S. payer coverage for >85% of commercial lives as of 2Q20 • 12% increase in prescriptions 2Q20 vs 1Q20 with strong refill rates	• Narcolepsy remains an unmet need; OSA has an extremely low drug treatment rate (~6%) • U.S: ~12 million diagnosed OSA patients • Geographic expansion ongoing in Europe: ~4 million diagnosed OSA patients; ~1 million with EDS[1] • Additional treatment uses include EDS in other sleep / CNS disorders
JZP-385 Phase 2 Essential Tremor	• Small molecule modulator of T-type calcium channels for ET, an area of significant unmet medical need • Broadens neuroscience pipeline into movement disorders • Anticipate Phase 2b study start-up activities in 2020 with a modified release formulation with once daily administration; Phase 2b study initiation planned early 2021	• Significant growth opportunity: ~11M ET prevalence in U.S. and Europe[1]; 2M diagnosed and 500K drug treated • Limited treatment options; tolerability issues and lack of efficacy with currently available pharmacotherapy • May have applicability in other neurological conditions
JZP-324 Phase 1 Cataplexy/EDS in Narcolepsy	• Lower-sodium oxybate extended release formulation • Currently in Phase 1 in healthy volunteers	• JZP-324 may provide optionality for patients with a lower sodium extended release formulation

[1] France, Germany, UK, Spain, Italy

ONCOLOGY PORTFOLIO

Tim
AML Patient

Strong Commercial and Development Capabilities

Oncology Portfolio

Revenue Diversification Driver

~$2B
Oncology sales 2015-2019

3
Products contributed $100M+ each in 2019

$445-525M
2020 oncology net sales guidance[1]

5
Novel approvals since 2015

Poised For Meaningful Growth

- Continued double-digit growth in portfolio
- Future revenue growth and diversification fueled by recent Zepzelca launch and planned JZP-458 launch mid-2021
- Expansion into solid tumors with Zepzelca
- Important growth opportunities for JZP-458 through expanded treatment and globalization
- Defitelio and Vyxeos remain important therapies for patients with significant unmet medical needs
- Investing in a deep and broad pipeline of innovative targets

[1] Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

Innovative Oncology Business Continues to Scale Rapidly

Expect significant growth momentum with Zepzelca launch in 2020 and JZP-458 planned launch in 2021

PORTFOLIO OF ATTRACTIVE PRODUCTS

ZEPZELCA (lurbinectedin) for injection 4 mg

First new treatment in 2L SCLC in over 20 years; expansion into solid tumors; synergistic with existing portfolio

Erwinaze® asparaginase *Erwinia chrysanthemi*

Treatment for hypersensitivity to *E. coli*-derived asparaginase

DEFITELIO® (defibrotide sodium) injection 80 mg/mL

Only therapy on the market to help adults and children who develop severe VOD, a complication from HSCT

Vyxeos™ (daunorubicin and cytarabine) 44 mg/100 mg per vial liposome for injection

First new advancement from traditional chemotherapy in more than 40 years for adults; overall survival benefit in secondary AML with durable remission

JZP-458

Modern recombinant *Erwinia* asparaginase for pediatric and adult patients with ALL hypersensitive to *E. coli*-derived asparaginase – expected to provide a reliable, consistent and high quality supply

STRONG GROWTH TRAJECTORY (REVENUE)



[1] Oncology net sales guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

Zepzelca Demonstrates High Strategic Fit

Area of significant unmet medical need

ZEPZELCA™ (lurbinectedin) for injection 4 mg

FDA accelerated approval June 2020 for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy

KEY HIGHLIGHTS

- Further diversifies commercial portfolio; expands into solid tumors
- Provides meaningful multi-hundred million dollar opportunity with 3 - 5 year route to peak
- Synergistic with existing portfolio
- Maximizing joint value generation with PharmaMar
- Prioritized and expedited launch plan
- July 2020: Quickly added to NCCN Clinical Practice Guidelines in Oncology for SCLC post approval

GROWTH OPPORTUNITIES

- SCLC: Growth opportunity in ~17,000 treated in 2L, plus ~8,000 failed in 1L and did not advance to 2L treatment
- Phase 3 ATLANTIS study top-line data expected 2H20
- Joint development plan with PharmaMar includes:
  - Evaluation of other tumor types
  - 1L SCLC in combination with I/O and other agents
  - 2L+ SCLC Combination (ATLANTIS)

Zepzelca: Rapid Path to FDA Approval & Launch

Demonstrating execution capabilities

ZEPZELCA™ (lurbinectedin) for injection 4 mg

6 months from closing to launch



JZP-458: Driven by Patient Need for Reliable, Life-Saving Therapy

Launch goal mid-2021 for recombinant *Erwinia* asparaginase for ALL

Significant Need for Reliable, Consistent, High Quality Supply

Global Expansion Opportunities — Europe and Japan

Treatment Population Expansion



Rapid progression from Phase 1 to pivotal study in <12 months

VALUE CREATION

Commercial Portfolio Driving Strong Financial Results

2020 ANI impacted by $200M payment to PharmaMar for exclusive U.S. rights to Zepzelca

TOTAL REVENUES[1]



ADJUSTED NET INCOME PER DILUTED SHARE[3]

Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted EPS.[4]

[1] 2016 to 2019 audited. [2] G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ. [3] Reconciliations of GAAP net income to non-GAAP adjusted net income can be found in the Appendix at the end of this presentation. [4] Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. The impact of this change to the company's 2020 non-GAAP adjusted net income and non-GAAP adjusted EPS guidance is approximately $175 million or $3.13 per diluted share, respectively, primarily related to the post-tax impact of the $200 million upfront payment made to PharmaMar in January 2020. For purposes of comparability, non-GAAP adjusted financial measures for 2016 to 2019 have been updated to reflect this change.

Robust and Productive Pipeline for Sustainable Growth

Targeted investments designed to fuel growth through 2025 and beyond

PRE-CLINICAL

Undisclosed targets
Neuroscience

CombiPlex
Exploratory activities

JZP-341
(Long-acting *Erwinia* asparaginase)[2]
ALL/other hematological malignancies

Recombinant pegaspargase[1]
Hematological malignancies

Pan-RAF Inhibitor Program
Raf & Ras mutant tumors

Oncology Targets
Ras/Raf/MAP kinase pathway[2]

Exosome targets
(NRAS, STAT3 and 3 others)[2]
Hematological malignancies/solid tumors

Defitelio
Exploratory activities

PHASE 1

JZP-324
Oxybate extended-release formulation

Vyxeos
Low Intensity Dosing for higher risk MDS[3]

Vyxeos + other approved therapies
- R/R AML or HMA Failure MDS[3]
- First-line, fit AML (Phase 1b)
- Low Intensity Therapy for first-line, unfit AML (Phase 1b)

IMGN632[1]
- R/R CD123+ Hematological malignancies
- **+/- venetoclax/azacitidine in** CD123+ AML (Phase 1b/2)

PHASE 2

JZP-385[4]
Essential tremor (Phase 2b)

Defitelio
- Prevention of aGvHD
- Prevention of CAR-T associated neurotoxicity

Vyxeos
- HR-MDS (EMSCO)[5]
- Newly diagnosed older adults with HR-AML[4,5]

Vyxeos + venetoclax
de novo or R/R AML[3]

PHASE 3

Xywav
Idiopathic hypersomnia

JZP-458
(recombinant *Erwinia* asparaginase)
ALL/LBL (pivotal Phase 2/3)

Zepzelca[6]
Relapsed SCLC (ATLANTIS)

Vyxeos
- AML or HR-MDS >60 yrs (AML18)[5]
- AML or HR-MDS >18 yrs (AML19)[5]
- Newly diagnosed adults with standard- and HR-AML (AMLSG)[5]
- Newly diagnosed <22 yrs with AML (COG)[5]

Neuroscience
Oncology

[1] Opt-in opportunity. [2] Partnered collaboration. [3] Jazz & MD Anderson Cancer Center collaboration study. [4] Planned. [5] Cooperative group study. [6] Exclusive U.S. license.

Corporate Development Strategy and Execution

Leveraging external innovation to deliver value to patients and shareholders

Preclinical Assets to Advance through Internal or External Research

Clinical Assets Aligned with Patient Needs and Pipeline Objectives

Commercial Assets to Grow and Diversify Revenue Base

Pan-RAF

JZP-341

CombiPlex

5 Exosome Targets

2 Ras/Raf/MAP kinase Targets

JZP-385

IMGN632

JZP-458

ZEPZELCA (lurbinectedin) for injection 4 mg

Erwinaze asparaginase Erwinia chrysanthemi

Vyxeos cytarabine and daunorubicin liposome for injection

XYREM (sodium oxybate) oral solution

SUNOSI (solriamfetol)

DEFITELIO (defibrotide sodium) injection 80 mg/mL

- Integrated approach to effectively evaluate opportunities, spanning pre-clinical to commercial
- Experienced deal-makers and significant capital available for deployment
- Operational expertise and scale to support development, regulatory and commercial success

Multiple Value Enhancing Catalysts in the Near Term

Pipeline advancements, clinical read-outs, regulatory approvals and product launches

2H20

- Xywav for narcolepsy launch 4Q20
- Xywav IH top-line data 4Q20
- Zepzelca ATLANTIS Phase 3 top-line data
- JZP-458 target BLA submission as early as year-end
- Defitelio for prevention of acute GvHD Phase 2 top-line data late 2020

1H21

- JZP-385 phase 2b trial to initiate early 2021
- Xywav for IH potential sNDA submission as early as 1Q21

Mid-2021

- JZP-458 target launch

2H21

- Xywav for IH targeted launch late 2021

Jazz Delivering Meaningful Shareholder Value

- Patient-Centric Innovation to Drive Our Strategy
- Experienced Leadership Team to Execute on Strategy and Deliver Value
- Strong Financial and Operational Track Record Generating >$2B in Annual Revenue
- High Value Neuroscience and Oncology Products Poised for Continued Growth and Diversification
- Global Commercial Footprint and Operations to Rapidly Advance and Scale Products
- Robust and Productive Development Pipeline Designed for Sustainable Growth
- Strong Balance Sheet and Cash Flow to Enable Strategic and Disciplined Capital Deployment
- Multiple Important Catalysts in 2020-2021 Providing Foundation for Transformative Growth


THANK YOU

APPENDIX

ZEPZELCA

XYWAV FOR IH

FINANCIAL OVERVIEW

ZEPZELCA

Trial Design

Lurbinectedin Monotherapy in Metastatic SCLC

Multicenter study of single-agent lurbinectedin in patients with 9 different tumor types, including second-line SCLC (NCT02454972)

PATIENT ELIGIBILITY (SCLC)

- ECOG PS 0-2
- One prior chemotherapy line
- Prior immunotherapy was allowed
- CNS metastases excluded

PRIMARY OBJECTIVE

- ORR by investigator assessment
- (RECIST v.1.1)

Prophylactic use of G-CSF was not permitted

[1] Trigo J, et al. Lancet Oncol. 2020

Phase 2 Study

Lurbinectedin Demonstrates Single Agent Anti-Tumor Activity

	Patient population	Lurbinectedin SCLC Cohort[1]		
		All CTFI (n = 105)	CTFI < 90 days (n = 45)	CTFI ≥ 90 days (n = 60)
INVESTIGATOR ASSESSED RESPONSE	**Response rate (95% CI)**	**35% (26% – 45%)**	**22% (11% – 37%)**	**45% (32% – 58%)**
	Median DoR (months) (95% CI)	5.3 (4.1 – 6.4)	4.7 (2.6 – 5.6)	6.2 (3.5 – 7.3)
IRC ASSESSED RESPONSE	Response rate (95% CI)	30% (22% – 40%)	13% (5% – 27%)	43% (31% – 57%)
	Median DoR (months) (95% CI)	5.1 (4.9 – 6.4)	4.8 (2.4 – 5.3)	5.3 (4.9 – 7.0)

[1] Lurbinectedin Prescribing Information

Duration of Response in Patients With SCLC Secondary Endpoint

Patients with resistant disease (CTFI < 90 days)



[1] Trigo J, et al. Lancet Oncol. 2020
Based on Investigator Assessed Responses and using Kaplan Meier estimates

Patients with sensitive disease (CTFI ≥ 90 days)



Safety Profile in Patients With SCLC[1]

No Grade 5 adverse reactions reported

Adverse Reactions ≥ 10%		All Grades	Grade 3-4
General	Fatigue	77%	12%
	Pyrexia	13%	0%
	Chest Pain	10%	0%
Musculoskeletal[2]	Musculoskeletal Pain	33%	4%
GI	Nausea	37%	0%
	Constipation	31%	0%
	Vomiting	22%	0%
	Diarrhea	20%	4%
	Abdominal Pain	11%	1%
Metabolism and Nutrition Disorders	Decreased Appetite	33%	1%
Respiratory, Thoracic and Mediastinal Disorders	Dyspnea	31%	6%
	Cough	20%	0%
Infections and Infestations	Respiratory tract infections	18%	5%
	Pneumonia	10%	7%
Nervous System Disorders	Peripheral Neuropathy	11%	1%
	Headache	10%	1%

[1] Lurbinectedin Prescribing Information, [2] Musculokeletal and Connective Tissue Disorders

Safety Profile in Patients With SCLC[1]

Laboratory Abnormalities > 20% Worsening from Baseline		All Grades	Grade 3-4
Hematology	Decreased leukocytes	79%	29%
	Decreased lymphocytes	79%	43%
	Decreased hemoglobin	74%	10%
	Decreased neutrophils	71%	46%
	Decreased platelets	37%	7%
	Febrile neutropenia[2]	*5%*	*5%*
Chemistry	Increased creatinine	69%	0%
	Increased alanine aminotransferase	66%	4%
	Increased glucose	52%	5%
	Decreased albumin	32%	1%
	Decreased sodium	31%	7%
	Increased aspartate aminotransferase	26%	2%
	Decreased magnesium	22%	0%

[1] Lurbinectedin Prescribing Information, [2] Trigo J, et al. Lancet Oncol. 2020

ATLANTIS Trial

Phase 3 randomized study of lurbinectedin and doxorubicin in 2L SCLC – expect data 2H20

Open-label, randomized, Phase 3 trial of lurbinectedin in combination with doxorubicin versus investigator's choice of chemotherapy (topotecan or CAV) in 2L SCLC

Patient eligibility: N = 613

- SCLC
- 1 prior platinum-containing regimen with CTFI ≥30 days
- ECOG PS ≤2
- Prior immune checkpoint inhibitor therapy was allowed

Randomization 1:1

Arm A:
Lurbinectedin (2 mg/m^2) & DOX (40 mg/m^2), D1 q3wk[a]

Lubrinectedin mono at 3.2 mg/m^2 q3w until PD

Arm B:
Topotecan 1.5 mg/m^2 D1-5 q3wk
OR
CAV: C 1000 mg/m^2, A 45 mg/m^2, V 2 mg fixed dose combination, D1 q3wk[a]

Primary endpoint: OS

Secondary endpoints: PFS, ORR by RECIST v.1.1

Stratification:

- ECOG (0 vs ≥1)
- CTFI (≥180 days, 90-179 days, <90 days)
- CNS involvement
- Prior PDL1/PD1 therapy
- Investigator's preference for control arm

- Mandatory primary prophylaxis for both arms

[a] Maximum 10 cycles

Jazz Pharmaceuticals

[1] Farago AF, et al. *Future Oncol*. 2019;15(3):231-239.

XYWAV FOR IH

Idiopathic Hypersomnia and Narcolepsy Symptomatology

Hypersomnolence disorders that share similar symptoms

Symptoms	Narcolepsy Type 1	Narcolepsy Type 2	Idiopathic Hypersomnia
Excess daytime sleepiness	✓	✓	✓
Sleep paralysis and hallucinations	✓	Sometimes	Occasionally
Cataplexy	✓	✗	✗
Difficulty staying asleep during the night	✓	Sometimes	✗
Refreshing (restorative) night-time sleep and naps	✓	Sometimes	Occasionally
Sleep inertia (residual profound sleepiness upon attempts to waken)	Occasionally	Sometimes	✓

Table adapted by Hypersomnia Foundation from Khan & Trotti 2015

Phase 3 study design

Xywav for Idiopathic Hypersomnia

- Top-line data expected 4Q20
- Targeting sNDA submission as early as 1Q21 and launch late 2021
- Primary efficacy endpoint: change in Epworth Sleepiness Scale score
- Key secondary endpoints: Patient Global Impression of Change and Idiopathic Hypersomnia Severity Scale total score; Other secondary endpoints: Clinical Global Impression of Change
- Safety was also assessed
- Planned enrollment: Approximately 140 subjects



FINANCIAL OVERVIEW

Strong Financial Position to Execute on Key Objectives

2020 ANI impacted by $200M payment to PharmaMar for exclusive U.S. rights to Zepzelca

TOTAL REVENUES[1]



ADJUSTED NET INCOME PER DILUTED SHARE[3]



Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted EPS.[4]

[1] 2016 to 2019 audited. [2] G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ. [3] Reconciliations of GAAP net income to non-GAAP adjusted net income can be found in the Appendix at the end of this presentation. [4] Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. The impact of this change to the company's 2020 non-GAAP adjusted net income and non-GAAP adjusted EPS guidance is approximately $175 million or $3.13 per diluted share, respectively, primarily related to the post-tax impact of the $200 million upfront payment made to PharmaMar in January 2020. For purposes of comparability, non-GAAP adjusted financial measures for 2016 to 2019 have been updated to reflect this change.

Strong Commitment to R&D

Prioritizing investments in our most important current and future revenue drivers

TOTAL R&D SPEND[1]



R&D SPEND[1] AS % OF TOTAL REVENUES



[1] Non-GAAP adjusted R&D spend, unaudited. Reconciliations of GAAP R&D to non-GAAP adjusted R&D can be found in the Appendix at the end of this presentation. Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. For purposes of comparability, non-GAAP adjusted financial measures for 2016 to 2019 have been updated to reflect this change. [2] G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

Summary of Share Repurchases Under Current Program

$431M remaining amount authorized under current share repurchase program

Since 2013, the company has returned $1.6B to shareholders through share repurchases

Share Repurchases	Dollar Amount Repurchased (in millions)	Shares Repurchased (in thousands)	Average Purchase Price Per Share
2Q20	$7	70	$106.93
1Q20	$139	1,131	$122.91
2019	$301	2,250	$133.97
2018	$524	3,530	$148.33
2017	$99	704	$140.34
2016	$18	175	$105.71
Program Total	**$1,089**	**7,861**	**$138.53**

Note: Amounts may not total due to rounding.

Non-GAAP Financial Measures

To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation and the accompanying tables. In particular, the company presents non-GAAP adjusted net income (and the related per share measure) and its line item components, as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP adjusted net income (and the related per share measure) and its line item components exclude from GAAP reported net income (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of non-GAAP adjustments and, as applicable, the income tax benefit related to an intra-entity intellectual property asset transfer and the impact of the U.S. Tax Cuts and Job Act (U.S. Tax Act). In this regard, the components of non-GAAP adjusted net income, including non-GAAP cost of product sales, non-GAAP SG&A expenses and non-GAAP R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure.

The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions.

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. For example, commencing in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. For purposes of comparability, non-GAAP adjusted financial measures for the years 2016 to 2019 have been updated to reflect this change. Accordingly, such payments are not excluded from its non-GAAP financial measures for years 2016 to 2019, or from 2020 non-GAAP adjusted net income guidance and non-GAAP adjusted net income per diluted share guidance as detailed in the reconciliation tables that follow. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Net Income

In millions, except per share amounts (unaudited)	2016	2017	2018	2019	2020 Guidance[3]
GAAP net income[1]	$ 396.8	$ 487.8	$ 447.1	$ 523.4	$190 - $270[3]
Intangible asset amortization	102.0	152.1	201.5	354.8	250 – 270[3]
Share-based compensation expense	98.8	106.9	102.4	110.6	120 – 135
Loss contingency	--	--	57.0	--	--
Impairment charges and disposal costs	--	--	44.0	--	136
Acquired IPR&D asset acquisition	--	--	--	48.3	--
Transaction and integration related costs	13.6	--	--	--	--
Expenses related to certain legal proceedings and restructuring	6.1	6.0	--	--	--
Non-cash interest expense	22.1	30.0	44.0	46.4	50 – 60
Loss on extinguishment and modification of debt	0.6	--	--	--	4
Income tax effect of above adjustments	(34.8)	(46.1)	(59.5)	(85.9)	(105) - (115)
Income tax benefit related to intra-entity intellectual property asset transfer	--	--	--	(112.3)	--
U.S. Tax Act impact	--	(148.8)	(7.5)	--	--
Non-GAAP adjusted net income[2]	$ 605.3	$ 587.9	$ 829.0	$ 885.2	$670 - $730
GAAP net income per diluted share[1]	$ 6.41	$ 7.96	$ 7.30	$ 9.09	$3.40 - $4.85
Non-GAAP adjusted net income per diluted share[2]	$ 9.78	$ 9.59	$ 13.54	$ 15.38	$11.90 - $13.00
Weighted-average ordinary shares used in diluted per share calculation	61.9	61.3	61.2	57.6	56

Note: Amounts may not total due to rounding.
[1] 2016 to 2019 audited. [2] Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. For purposes of comparability, non-GAAP adjusted financial measures for 2016 to 2019 have been updated to reflect this change. [3] Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

Reconciliation of GAAP R&D to Non-GAAP Adjusted R&D Expense

In millions (unaudited)	**2016**	**2017**	**2018**	**2019**	**2020G[3]**
GAAP R&D expense[1]	$162.3	$198.4	$226.6	$299.7	$302 - $338
Share-based compensation expense	(15.3)	(17.9)	(19.0)	(25.2)	(27-33)
Transaction and integration related costs	(0.5)	--	--	--	--
Non-GAAP adjusted R&D expense[2]	$146.5	$180.6	$207.6	$274.5	$275 - $305

Note: Amounts may not total due to rounding.
[1] 2016 to 2019 audited. [2] Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. For purposes of comparability, non-GAAP adjusted financial measures for 2016 to 2019 have been updated to reflect this change. [3] G=Guidance; Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

Oxybate Landscape

Oxybate net sales and AG royalties expected to contribute meaningfully to total revenues



[1] Hikma AG entry on January 1, 2023 with initial 6-month AG term and optional AG terms from July 1, 2023 to December 31, 2027; Amneal, Lupin and Par AG entry with low single-digit volume restrictions on July 1, 2023; Launch dates provided in settlement agreements with ANDA filers could be accelerated under certain circumstances. [2] Hikma has a license to launch its generic product as of July 1, 2023, but it will no longer have the right to sell an AG product through the Xyrem REMS if it elects to do so. [3] Subject to obtaining or maintaining ANDA approval.

Glossary of Terms

1L = First-Line
2L = Second-Line
AG = Authorized Generic
aGvHD = Acute Graft vs Host Disease
ALL = Acute Lymphoblastic Leukemia
AML = Acute Myeloid Leukemia
AMLSG = AML Study Group
ANDA = Abbreviated New Drug Application
ANI = Adjusted Net Income
ASCO = American Society of Clinical Oncology
ATLANTIS = Phase 3 Clinical Study of lurbinectedin in SCLC
BLA = Biologics License Application
CAGR = Compound Annual Growth Rate
CAR-T = Chimeric Antigen Receptor T-cell Therapy
CAV = Cyclophosphamide, Doxorubicin and Vincristine
CI = Confidence Interval
COG = Children's Oncology Group
COVID-19 = Coronavirus Disease of 2019
CNS = Central Nervous System
CTFI = Chemotherapy Free Interval
DBRWP = Double Blind Randomized Withdrawal Period
DNRI = Dopamine and Norepinephrine Reuptake Inhibitor
DoR = Duration of Response
E = Estimated
ECOG = Eastern Cooperative Oncology Group
EDS = Excessive Daytime Sleepiness
EMA = European Medicines Agency
EMSCO = European Myelodysplastic Syndromes Cooperative Group
EPS = Earnings Per Share
ET = Essential Tremor
FDA = U.S. Food and Drug Administration
GAAP = Generally Accepted Accounting Principles
G-CSF = Granulocyte Colony-Stimulating Factor
GHB = Gamma Hydroxybutyrate
GI = Gastrointestinal
GvHD = Graft vs Host Disease
HCP = Health Care Professional
HMA = Hypomethylating Agent
HR-AML = High-Risk AML
HR-MDS = High-Risk MDS
HSCT = Hematopoietic Stem Cell Transplant
IH = Idiopathic Hypersomnia
IMGN = ImmunoGen, Inc.
IND = Investigational New Drug Application
I/O = Immuno-Oncology
IPR&D = In-Process Research and Development
IRC = Independent Review Committee
LBL = Lymphoblastic Lymphoma
LPI = Last Patient In
LTM = Last 12 Months
M&A = Mergers and Acquisitions
MOA = Mechanism of Action
MDS = Myelodysplastic Syndrome
NCCN = National Comprehensive Cancer Network
NDA = New Drug Application
ODD = Orphan Drug Designation
OLE = Open Label Extension
ORR = Overall Response Rate
OS = Overall Survival
OSA = Obstructive Sleep Apnea
PD = Disease Progression
Pfenex = Pfenex, Inc.
PFS = Progression Free Survival
PharmaMar = Pharma Mar, S.A.
PS = Performance Status
R&D = Research & Development
RECIST = Response Evaluation Criteria in Solid Tumors
REMS = Risk Evaluation Mitigation Strategy
R/R = Relapsed/Refractory
SCLC = Small Cell Lung Cancer
SG&A = Selling, General & Administrative Expense
sNDA = Supplemental New Drug Application
TSR = Total Shareholder Return
VOD = Hepatic Veno-Occlusive Disease
YE = Year-End

Boxed Warning

Xyrem® (sodium oxybate)

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE

Central Nervous System Depression

Xyrem (sodium oxybate) is a CNS depressant. In clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in adult patients treated with Xyrem. Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants.

Abuse and Misuse

Xyrem® (sodium oxybate) is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.

Because of the risks of CNS depression and abuse and misuse, Xyrem is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS *[see Warnings and Precautions (5.3)]*.

.

Xyrem (sodium oxybate) prescribing information

Boxed Warning

Vyxeos® (daunorubicin and cytarabine) liposome for injection

WARNING:
DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN- AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors *(5.1)*.

Vyxeos prescribing information

Boxed Warning

Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution

WARNING:
CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE

Central Nervous System Depression
XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses *[see Warnings and Precautions (5.1, 5.4)]*. Many patients who received XYWAV during clinical trials in narcolepsy were receiving central nervous system stimulants *[see Clinical Trials (14.1)]*.

Abuse and Misuse
The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death *[see Warnings and Precautions (5.2)].*

Because of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS *[see Warnings and Precautions (5.3)]*.